Ionis Pharmaceuticals, Inc. (BMV:IONS)
Mexico
· Delayed Price · Currency is MXN 1,150.00
+50.00 (4.55%)
At close: Sep 24, 2025
Ionis Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 943.71 | 705.14 | 787.65 | 587.37 | 810.46 | Upgrade
|
| Revenue Growth (YoY) | 33.83% | -10.47% | 34.10% | -27.53% | 11.13% | Upgrade
|
| Cost of Revenue | 931.53 | 912.75 | 908.76 | 847.26 | 654.3 | Upgrade
|
| Gross Profit | 12.18 | -207.61 | -121.11 | -259.9 | 156.16 | Upgrade
|
| Selling, General & Admin | 393.87 | 267.47 | 232.62 | 150.3 | 186.35 | Upgrade
|
| Operating Expenses | 393.87 | 267.47 | 232.62 | 150.3 | 186.35 | Upgrade
|
| Operating Income | -381.68 | -475.08 | -353.73 | -410.19 | -30.19 | Upgrade
|
| Interest Expense | -90.54 | -90.45 | -81.46 | -8.12 | -9.35 | Upgrade
|
| Interest & Investment Income | 97.77 | 107.02 | 89.04 | 25.33 | 10.04 | Upgrade
|
| Other Non Operating Income (Expenses) | -15.36 | 1.33 | 0.71 | -7.27 | -1.13 | Upgrade
|
| EBT Excluding Unusual Items | -389.82 | -457.18 | -345.44 | -400.26 | -30.62 | Upgrade
|
| Gain (Loss) on Sale of Investments | 10.22 | -2.89 | -1.91 | -7.33 | 10.1 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 149.6 | - | Upgrade
|
| Other Unusual Items | - | - | 13.39 | - | -8.63 | Upgrade
|
| Pretax Income | -379.6 | -460.07 | -333.97 | -257.99 | -29.15 | Upgrade
|
| Income Tax Expense | 1.79 | -6.17 | 32.32 | 11.74 | -0.55 | Upgrade
|
| Earnings From Continuing Operations | -381.39 | -453.9 | -366.29 | -269.72 | -28.6 | Upgrade
|
| Net Income | -381.39 | -453.9 | -366.29 | -269.72 | -28.6 | Upgrade
|
| Net Income to Common | -381.39 | -453.9 | -366.29 | -269.72 | -28.6 | Upgrade
|
| Shares Outstanding (Basic) | 160 | 150 | 143 | 142 | 141 | Upgrade
|
| Shares Outstanding (Diluted) | 160 | 150 | 143 | 142 | 141 | Upgrade
|
| Shares Change (YoY) | 7.02% | 4.42% | 0.95% | 0.59% | 1.01% | Upgrade
|
| EPS (Basic) | -2.38 | -3.04 | -2.56 | -1.90 | -0.20 | Upgrade
|
| EPS (Diluted) | -2.38 | -3.04 | -2.56 | -1.90 | -0.20 | Upgrade
|
| Free Cash Flow | -320.03 | -546.23 | -331.32 | -290.09 | 18.84 | Upgrade
|
| Free Cash Flow Per Share | -2.00 | -3.65 | -2.31 | -2.04 | 0.13 | Upgrade
|
| Gross Margin | 1.29% | -29.44% | -15.38% | -44.25% | 19.27% | Upgrade
|
| Operating Margin | -40.45% | -67.37% | -44.91% | -69.84% | -3.72% | Upgrade
|
| Profit Margin | -40.41% | -64.37% | -46.50% | -45.92% | -3.53% | Upgrade
|
| Free Cash Flow Margin | -33.91% | -77.46% | -42.06% | -49.39% | 2.33% | Upgrade
|
| EBITDA | -369.24 | -463.13 | -340.88 | -393.45 | -12.35 | Upgrade
|
| EBITDA Margin | -39.13% | -65.68% | -43.28% | -66.98% | -1.52% | Upgrade
|
| D&A For EBITDA | 12.45 | 11.95 | 12.85 | 16.74 | 17.84 | Upgrade
|
| EBIT | -381.68 | -475.08 | -353.73 | -410.19 | -30.19 | Upgrade
|
| EBIT Margin | -40.45% | -67.37% | -44.91% | -69.84% | -3.72% | Upgrade
|
| Revenue as Reported | 943.71 | 705.14 | 787.65 | 587.37 | 810.46 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.